Tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free Cosopt®) in patients with open-angle glaucoma or ocular hypertension

Tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free Cosopt®) in patients with open-angle glaucoma or ocular hypertension

Cindy Hutnik1, David Neima2, Fahim Ibrahim3, Robert Scott4, Julie Vaillancourt5, Denis Haine5, John S Sampalis5, Natacha Bastien6, Sylvain Foucart61Ivey Eye Institute, St Joseph Healthcare, London, Ontario, Canada; 2New Westminster, British Columbia, Canada; 3Point Edward, Ontario, Canada; 4Kentvill...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cindy Hutnik, David Neima, Fahim Ibrahim, et al
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2010
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/95281ebdbef64e6db5b2468917e524bf
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:95281ebdbef64e6db5b2468917e524bf
record_format dspace
spelling oai:doaj.org-article:95281ebdbef64e6db5b2468917e524bf2021-12-02T05:09:37ZTolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free Cosopt®) in patients with open-angle glaucoma or ocular hypertension1177-54671177-5483https://doaj.org/article/95281ebdbef64e6db5b2468917e524bf2010-06-01T00:00:00Zhttp://www.dovepress.com/tolerability-and-effectiveness-of-preservative-free-dorzolamidendashti-a4596https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Cindy Hutnik1, David Neima2, Fahim Ibrahim3, Robert Scott4, Julie Vaillancourt5, Denis Haine5, John S Sampalis5, Natacha Bastien6, Sylvain Foucart61Ivey Eye Institute, St Joseph Healthcare, London, Ontario, Canada; 2New Westminster, British Columbia, Canada; 3Point Edward, Ontario, Canada; 4Kentville, Nova Scotia, Canada; 5JSS Medical Research, Westmount, Quebec, Canada; 6Merck Frosst Canada Ltd, Kirkland, Quebec, CanadaPurpose: To assess the effect of preservative-free dorzolamide–timolol on nonvisual symptoms and intraocular pressure (IOP) in newly diagnosed and untreated patients with open-angle glaucoma or ocular hypertension.Methods: This was a prospective, 8-week, open-label, Canadian multicenter study. All patients were treated with preservative-free dorzolamide–timolol formulation. The primary outcome was the change in the nonvisual symptom score of the Glaucoma Symptom Scale (GSS-SYMP-6) from baseline to 8 weeks. Secondary effectiveness outcome measures were absolute and percent changes in IOP from baseline to 4 and 8 weeks.Results: One hundred and seventy-eight patients were enrolled. Mean (SD) age was 65.6 (12.1) years and 90 (50.6%) were females. There were 92 patients diagnosed with open-angle glaucoma, 62 with ocular hypertension, and 23 with both diseases (diagnosis was missing for one patient). The mean (SD) GSS-SYMP-6 score increased from 73.6 (21.8) at baseline to 76.1 (20.7) at 8 weeks (P = 0.097). Mean (SD) IOP significantly decreased by 11.7 (5.1) mmHg at 4 weeks (P < 0.001) and by 11.5 (5.3) mmHg at 8 weeks (P < 0.001), representing reductions of -38.5% (P < 0.001) and -38.0% (P < 0.001), respectively.Conclusion: Preservative-free dorzolamide–timolol does not increase eye discomfort while significantly reducing IOP in patients with open-angle glaucoma or ocular-hypertension. Keywords: open-angle glaucoma, ocular hypertension, GSS-SYMP-6, intraocular pressure, dorzolamide–timolol, preservative-free Cindy HutnikDavid NeimaFahim Ibrahimet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 581-590 (2010)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Cindy Hutnik
David Neima
Fahim Ibrahim
et al
Tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free Cosopt®) in patients with open-angle glaucoma or ocular hypertension
description Cindy Hutnik1, David Neima2, Fahim Ibrahim3, Robert Scott4, Julie Vaillancourt5, Denis Haine5, John S Sampalis5, Natacha Bastien6, Sylvain Foucart61Ivey Eye Institute, St Joseph Healthcare, London, Ontario, Canada; 2New Westminster, British Columbia, Canada; 3Point Edward, Ontario, Canada; 4Kentville, Nova Scotia, Canada; 5JSS Medical Research, Westmount, Quebec, Canada; 6Merck Frosst Canada Ltd, Kirkland, Quebec, CanadaPurpose: To assess the effect of preservative-free dorzolamide–timolol on nonvisual symptoms and intraocular pressure (IOP) in newly diagnosed and untreated patients with open-angle glaucoma or ocular hypertension.Methods: This was a prospective, 8-week, open-label, Canadian multicenter study. All patients were treated with preservative-free dorzolamide–timolol formulation. The primary outcome was the change in the nonvisual symptom score of the Glaucoma Symptom Scale (GSS-SYMP-6) from baseline to 8 weeks. Secondary effectiveness outcome measures were absolute and percent changes in IOP from baseline to 4 and 8 weeks.Results: One hundred and seventy-eight patients were enrolled. Mean (SD) age was 65.6 (12.1) years and 90 (50.6%) were females. There were 92 patients diagnosed with open-angle glaucoma, 62 with ocular hypertension, and 23 with both diseases (diagnosis was missing for one patient). The mean (SD) GSS-SYMP-6 score increased from 73.6 (21.8) at baseline to 76.1 (20.7) at 8 weeks (P = 0.097). Mean (SD) IOP significantly decreased by 11.7 (5.1) mmHg at 4 weeks (P < 0.001) and by 11.5 (5.3) mmHg at 8 weeks (P < 0.001), representing reductions of -38.5% (P < 0.001) and -38.0% (P < 0.001), respectively.Conclusion: Preservative-free dorzolamide–timolol does not increase eye discomfort while significantly reducing IOP in patients with open-angle glaucoma or ocular-hypertension. Keywords: open-angle glaucoma, ocular hypertension, GSS-SYMP-6, intraocular pressure, dorzolamide–timolol, preservative-free
format article
author Cindy Hutnik
David Neima
Fahim Ibrahim
et al
author_facet Cindy Hutnik
David Neima
Fahim Ibrahim
et al
author_sort Cindy Hutnik
title Tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free Cosopt®) in patients with open-angle glaucoma or ocular hypertension
title_short Tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free Cosopt®) in patients with open-angle glaucoma or ocular hypertension
title_full Tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free Cosopt®) in patients with open-angle glaucoma or ocular hypertension
title_fullStr Tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free Cosopt®) in patients with open-angle glaucoma or ocular hypertension
title_full_unstemmed Tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free Cosopt®) in patients with open-angle glaucoma or ocular hypertension
title_sort tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free cosopt®) in patients with open-angle glaucoma or ocular hypertension
publisher Dove Medical Press
publishDate 2010
url https://doaj.org/article/95281ebdbef64e6db5b2468917e524bf
work_keys_str_mv AT cindyhutnik tolerabilityandeffectivenessofpreservativefreedorzolamideampndashtimololpreservativefreecosoptampreginpatientswithopenangleglaucomaorocularhypertension
AT davidneima tolerabilityandeffectivenessofpreservativefreedorzolamideampndashtimololpreservativefreecosoptampreginpatientswithopenangleglaucomaorocularhypertension
AT fahimibrahim tolerabilityandeffectivenessofpreservativefreedorzolamideampndashtimololpreservativefreecosoptampreginpatientswithopenangleglaucomaorocularhypertension
AT etal tolerabilityandeffectivenessofpreservativefreedorzolamideampndashtimololpreservativefreecosoptampreginpatientswithopenangleglaucomaorocularhypertension
_version_ 1718400544392871936

Ejemplares similares